How Collaborative Value Engineering And Continuous Improvement Enhance The CDMO Relationship

Source: Cambrex

By Adam Hopper, Cambrex


The search for vaccines and treatments throughout the COVID-19 pandemic, combined with the backlog of non-COVID therapies that piled up during the pandemic’s initial months, has driven a surge in demand for contract development and manufacturing organization (CDMO) production capacity. As CDMOs have transformed to meet that need — adding new facilities and equipment, as well as introducing operational strategies to overcome burdens related to the pandemic — the challenge for commercial pharmaceutical companies has evolved from simply finding a CDMO partner with adequate capacity.

Commercial pharma companies require a CDMO partner focused on continuous improvement and value engineering to maintain viable margins: cost structure and supply chain risk mitigation, as well as overall product portfolio management. This need is particularly pressing for pharma companies operating in the generics or branded over-the-counter (OTC) spaces, since extending the product life cycle depends on lowering costs in response to competition-driven price pressure. To this end, a collaborative partnership model is effective in optimizing profitability management and product life cycles.

Cambrex leverages several strategies to value engineer processes surrounding existing commercial products. We start by assembling a dedicated, cross-functional team touching on all impactful areas, including quality, regulatory, process engineering, and procurement. That team identifies opportunities to create value and presents its findings to the client (be it a similar cross-functional team or a project management team). Then, both parties align on priorities and present their findings, as well as proposed solutions, to their corresponding senior leadership on a monthly, quarterly, semi-annual, or annual basis. Based on that information, leadership at both Cambrex and the client can approve an aligned, regularly updated strategy that considers changing priorities and upcoming milestones.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online